LIB Therapeutics is a privately held, late-stage biopharmaceutical company dedicated to bringing novel, safe and convenient subcutaneous and oral PCSK9 inhibitors to the millions of patients at very high and high-risk of cardiovascular disease (CVD), and the 30 million with familial hypercholesterolemia (FH), who require additional large reductions in low density lipoprotein-cholesterol (LDL-C) despite maximally tolerated statins and other lipid lowering agents.
Company Details
- Employees
- 11
- Founded
- -
- Address
- 5375 Medpace Way, Cincinnati,oh 45227-1543,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.libtherapeutics.com/
- Keywords
- cardiovascular, LDL-C, lerodalcibep.
- HQ
- Cincinnati, OH
Lib Therapeutics Questions
Lib Therapeutics's website is https://www.libtherapeutics.com/
Lib Therapeutics's LinkedIn profile is https://www.linkedin.com/company/libtherapeutics
Lib Therapeutics has
11 employees.
View email and phone details for 11
employees at Lib Therapeutics.
Lib Therapeutics's industry is
Biotechnology Research
Lib Therapeutics's top competitors are
Clarametyx Biosciences,
Medexus Pharmaceuticals,
Journey Biosciences,
North Star Rx Consulting,
Ionis Pharmaceuticals, Inc.,
Dalcor Pharmaceuticals,
Kurome Therapeutics, Inc.,
Cinrx Pharma,
Hasten Biopharmaceutical Co., Ltd.,
Novelmed.
Lib Therapeutics's categories are Biotechnology Research
Lib Therapeutics's founding year is 2015
